Prut Koonalintip

Dr. Prut Koonalintip

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2024 in Life
Verified
Journal Article
Open access
PDF file
PKPrut Koonalintip
Prut Koonalintip
KPKatherine Phillips
Katherine Phillips
BWBenjamin R Wakerley
Benjamin R Wakerley
Long-term frequent use of acute pain medication for the treatment of headaches has paradoxically been shown to increase the frequency of headaches. So-called medication-overuse headache (MOH) is particularly problematic in patients with migraine who overuse triptans and opioids. Prevention through education remains the most important management strategy. Once established, MOH can be difficult to treat. Although complete or near-complete withdrawal of acute pain medication for 8–12 weeks has been shown to benefit most patients, this can be hard to achieve. The use of OnabotulinumtoxinA and drugs that target the calcitonin gene-related peptide system for the prevention of migraines have been shown to benefit patients with MOH. Furthermore, the use of novel acute pain medication for migraines, including Gepants and Ditans, which do not cause MOH, are likely to improve patient outcomes. In this review article we examine the following: the burden of MOH; who develops MOH; the pathophysiological mechanisms; and the treatment strategies.

26 February 2025 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
PKPrut Koonalintip
Prut Koonalintip
SYSuppakorn Yamutai
Suppakorn Yamutai
SSSuwanna Setthawatcharawanich
Suwanna Setthawatcharawanich
TTTherdpong Thongseiratch
Therdpong Thongseiratch
PCPly Chichareon
Ply Chichareon
BWBenjamin R. Wakerley
Benjamin R. Wakerley
Medication-overuse headache (MOH) is the most common secondary headache disorder, resulting from or leading to the frequent use of acute headache medications. Despite the availability of various treatment strategies, the optimal approach remains uncertain. This network meta-analysis (NMA) aimed to evaluate the comparative efficacy of different strategies for managing MOH, focusing on reducing monthly headache days. We systematically reviewed randomized controlled trials (RCTs) comparing withdrawal strategies, including bridging therapies, the use of concurrent migraine prevention drugs, and additional education, in adult patients diagnosed with MOH. The primary outcome was the reduction in monthly headache days. Eligible studies were analyzed using a random-effects NMA model, integrating both direct and indirect evidence. Treatments were ranked using p-scores, and risk of bias was assessed using the Cochrane risk of bias tool 2.0. Sixteen RCTs involving 3,000 participants were included. Compared to control, combination therapies, such as abrupt withdrawal with oral prevention and greater occipital nerve block and restriction of overused acute medication with oral prevention and Calcitonin gene-related peptide (CGRP) therapies, demonstrated the greatest efficacy, with reductions in monthly headache days of -10.6 (95% CI: [-15.03; -6.16]) and -8.47 (95% CI: [-12.78; -4.15]), respectively. Headache prevention strategies, including oral prevention (P), anti-calcitonin gene-related peptide (receptor) (CGRP(R)) therapies (A), and botulinum toxin (B) showed significant in reduction of monthly headache days, but no single initial prevention strategy demonstrates superior efficacy over the others. In contrast, abrupt withdrawal alone (W) showed no significant efficacy, with a mean difference of -2.77 (95% CI: [-5.74; 0.20]). Combination therapies, including anti-CGRP(R) therapies and nerve blocks, appear to be the most effective strategies for MOH management, highlighting their potential as initial treatment options. While headache prevention strategies demonstrated similar efficacy, abrupt withdrawal alone was insufficient. The observed reduction in headache frequency after treatment suggests that strategies with greater efficacy may help lower the likelihood of MOH relapse. PROSPERO, CRD 42024620487.

25 September 2024 in Life
Verified
Journal Article
Open access
PDF file
KPKatherine Phillips
Katherine Phillips
PKPrut Koonalintip
Prut Koonalintip
BWBenjamin R Wakerley
Benjamin R Wakerley
Migraine affects almost one in five women of reproductive age. Therefore, understanding its impact on pregnancy outcomes and how to manage migraine safely in pregnancy are of particular importance. This review will summarise the clinical course of migraine during pregnancy, the management of women presenting with headaches during pregnancy, the management of migraine during pregnancy and summarise what is known about how migraine and migraine medications impact pregnancy outcomes.

16 April 2025 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
PKPrut Koonalintip
Prut Koonalintip
SYSuppakorn Yamutai
Suppakorn Yamutai
SSSuwanna Setthawatcharawanich
Suwanna Setthawatcharawanich
TTTherdpong Thongseiratch
Therdpong Thongseiratch
PCPly Chichareon
Ply Chichareon
BWBenjamin R. Wakerley
Benjamin R. Wakerley

22 May 2026 in Journal of Neurology
Verified
Journal Article
Open access
CSChernkhuan Stonsaovapak
Chernkhuan Stonsaovapak
NKNantawan Koonalinthip
Nantawan Koonalinthip
PKPrut Koonalintip
Prut Koonalintip
CPChatkaew Pongmala
Chatkaew Pongmala
PTPim Terachinda
Pim Terachinda
Objective: This systematic review and network meta-analysis compares the individual and synergistic efficacy of external sensory cueing modalities to establish a treatment hierarchy for optimizing spatiotemporal gait parameters in individuals with Parkinson’s disease (PD). Methods: A systematic literature search was conducted across Scopus, PubMed, Cochrane CENTRAL, and ClinicalTrials.gov. Randomized controlled trials (RCTs) evaluating visual, auditory, somatosensory, or combined cueing modalities in individuals with PD were eligible. Trials were required to compare at least two active cueing modalities or an active modality against a control condition and report gait velocity and/or stride length. Results: Thirty-three RCTs ( n = 1118 participants) were included. For gait velocity, somatosensory (MD = 0.12 m/s; 95% CI 0.04–0.19) and visual cues (MD = 0.11 m/s; 95% CI 0.02–0.20) demonstrated significant improvements over control. For stride length, visual (MD = 11.46 cm; 95% CI 6.40–16.51), somatosensory (MD = 10.74 cm; 95% CI 7.04–14.44), and auditory cues (MD = 5.25 cm; 95% CI 0.43–10.06) all yielded statistically significant benefits. P -score rankings identified somatosensory cues as the top-ranked modality for gait velocity ( P -score = 0.71) and visual cues for stride length ( P -score = 0.83). Global heterogeneity was substantial ( I 2 = 64–90%), and no significant publication bias was detected. Conclusions: External sensory cueing improves spatiotemporal gait parameters in PD, with somatosensory and visual cues emerging as the most effective modalities for enhancing gait velocity and stride length. Both modalities outperformed standalone auditory stimulation, providing a data-driven hierarchy to guide evidence-based cueing selection in clinical practice.

23 January 2026 in PLOS ONE
Verified
Journal Article
Open access
PBPattira Boonsri
Pattira Boonsri
SYSuppakorn Yamutai
Suppakorn Yamutai
PTPramot Tanutit
Pramot Tanutit
JSJirakit Sattayapornpipat
Jirakit Sattayapornpipat
CCChariyawan Charalsawadi
Chariyawan Charalsawadi
PKPat Korathanakhun
Pat Korathanakhun
Objectives: Previous muscle imaging studies of GNE myopathy are limited to the lower extremities. This study aimed to use whole-body MRI to differentiate between GNE myopathy and other young adult-onset hereditary myopathies. Materials and methods: This retrospective cohort study recruited patients with GNE myopathy or young adult-onset hereditary with limb girdle weakness pattern followed up in a single-center neuromuscular clinical registry between 2019 and 2023. Fatty tissue replacement was evaluated using a 5-point scale using T1-weighted images (T1WI) and proton-density fat fractions (PDFF) from mDIXON Quant images. Inflammation was evaluated using short tau inversion recovery imaging. The distribution and severity of muscle involvement in GNE myopathy were visualized using heat maps, and the parameters were tested for significance. Results: Of 103 patients, five with GNE myopathy and 10 with young adult-onset hereditary myopathy were recruited. Prominent fatty tissue replacement was seen in specific muscles with subtle active inflammation in GNE myopathy. The comparison of fatty tissue replacement between GNE and other young adult-onset hereditary myopathies exhibited the classic quadriceps sparing pattern in GNE myopathy group. Beyond these findings, latissimus dorsi showed the significantly lower fatty tissue replacement in the GNE group (median [IQR] of T1WI grade 1 [0, 1] vs. 3 [1, 3.4], p = 0.04) and mean (± S.D.) of PDFF in mDIXON Quant (19.0 ± 9.7 vs. 42.6 ± 22.7, p = 0.04). Conclusion: The latissimus dorsi sparing out of proportion to periscapular weakness would be a novel differentiative feature of GNE myopathy.